Acalabrutinib is a potent and selective BTK (Bruton¡¯s tyrosine kinase) inhibitor. BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors. Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders. BTK inhibitors targeting B cell receptor signaling and other survival mechanism showed great promise for the treatment of chronic lymphocytic leukemia (CLL)s holds great promise.

June 21, 2017

prudect name : Acalabrutinib is a potent and selective BTK (Bruton¡¯s tyrosine kinase) inhibitor. BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors. Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders. BTK inhibitors targeting B cell receptor signaling and other survival mechanism showed great promise for the treatment of chronic lymphocytic leukemia (CLL)s holds great promise.
Acalabrutinib (ACP-196)

Synonyms: CAS NO: 1420477-60-6Molecular Formula: C₂₆H₂₃N₇O₂Molecular Weight: 465.52Purity: 98% minSolubility: In DMSOStorage: -20 oC

249921-19-5 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18501163